Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases

J Neuroimmunol. 2006 Jul;176(1-2):198-215. doi: 10.1016/j.jneuroim.2006.03.027.

Abstract

Multiple sclerosis is considered a disease of myelin destruction; Parkinson's disease (PD), one of dopaminergic neuron depletion; ALS, a disease of motor neuron death; and Alzheimer's, a disease of plaques and tangles. Although these disorders differ in important ways, they also have common pathogenic features, including inflammation, genetic mutations, inappropriate protein aggregates (e.g., Lewy bodies, amyloid plaques), and biochemical defects leading to apoptosis, such as oxidative stress and mitochondrial dysfunction. In most disorders, it remains uncertain whether inflammation and protein aggregation are neurotoxic or neuroprotective. Elucidating the mechanisms that orchestrate neuronal diseases should facilitate development of neuroprotective and neurorestorative strategies.

Publication types

  • Clinical Conference
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / etiology
  • Alzheimer Disease / immunology
  • Amyotrophic Lateral Sclerosis / drug therapy
  • Amyotrophic Lateral Sclerosis / etiology
  • Amyotrophic Lateral Sclerosis / immunology
  • Animals
  • Caspase 1 / physiology
  • Humans
  • Inflammation / complications
  • Magnetic Resonance Imaging
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / etiology*
  • Multiple Sclerosis / immunology
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / etiology*
  • Neurodegenerative Diseases / immunology
  • Neuroprotective Agents / therapeutic use*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / etiology
  • Parkinson Disease / immunology
  • Stroke / drug therapy

Substances

  • Neuroprotective Agents
  • Caspase 1